LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)

News

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com